Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke
Associated Therapies
-

Diuretics and Angiotensin-Receptor Blocker Agents in Patients With Stage I Hypertension

First Posted Date
2009-09-03
Last Posted Date
2015-02-12
Lead Sponsor
Hospital de Clinicas de Porto Alegre
Target Recruit Count
655
Registration Number
NCT00971165
Locations
🇧🇷

Hospital de Clínicas de Porto Alegre, UFRGS, Porto Alegre, RS, Brazil

🇧🇷

Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

Olmesartan Comparison to Losartan in Hypertensive Subjects

First Posted Date
2009-07-30
Last Posted Date
2011-03-09
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
941
Registration Number
NCT00949884

The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-07-22
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
13
Registration Number
NCT00943852

Efficacy and Safety of Amlodipine and Losartan in Patients With Essential Hypertension

Phase 2
Completed
Conditions
First Posted Date
2009-07-20
Last Posted Date
2009-07-20
Lead Sponsor
Hanmi Pharmaceutical Company Limited
Target Recruit Count
320
Registration Number
NCT00942344
Locations
🇰🇷

14 sites in Korea, Seoul, Busan, etc., Korea, Republic of

Efficacy/Safety of Amlodipine Plus Losartan Versus Losartan in Patients With Essential Hypertension

Phase 3
Completed
Conditions
Interventions
First Posted Date
2009-07-16
Last Posted Date
2009-07-16
Lead Sponsor
Hanmi Pharmaceutical Company Limited
Target Recruit Count
142
Registration Number
NCT00940680
Locations
🇰🇷

9 sites in Korea, Seoul, Daegu, etc., Korea, Republic of

MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension

Phase 3
Completed
Conditions
Interventions
First Posted Date
2009-04-27
Last Posted Date
2009-07-09
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
428
Registration Number
NCT00888355

A Study to Investigate the Antihypertensive Efficacy of MK0954

Phase 3
Completed
Conditions
Interventions
First Posted Date
2009-04-23
Last Posted Date
2009-07-14
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
366
Registration Number
NCT00887250

A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)

First Posted Date
2009-04-23
Last Posted Date
2015-08-27
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
122
Registration Number
NCT00886600

A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)

First Posted Date
2009-04-16
Last Posted Date
2015-08-27
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
576
Registration Number
NCT00882440
© Copyright 2024. All Rights Reserved by MedPath